Therapeutic drug management of the novel agents for multiple myeloma
Project/Area Number |
26461414
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Hematology
|
Research Institution | Akita University |
Principal Investigator |
Takahashi Naoto 秋田大学, 医学(系)研究科(研究院), 教授 (80344753)
|
Co-Investigator(Kenkyū-buntansha) |
三浦 昌朋 秋田大学, 医学部, 教授 (30265194)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 多発性骨髄腫 / 血中濃度 / 治療効果 / レナリドミド / T細胞 / NK細胞 / 薬物トランスポーター / 制御性T細胞 / T/Nk細胞プロファイリング / 薬物輸送蛋白 / SNP / BIM / 薬物濃度 |
Outline of Final Research Achievements |
Lenalidomide (Len) is an immuno-modulatory key drug for multiple myeloma (MM). However, adverse events (AEs) make continuation of Len difficult for some patients especially for elderly patients. The purpose of this study is to investigate the safe and effective plasma concentration of Len and the anti-tumor immune response change. Forty patients were enrolled in this study. The plasma concentrations of Len were analyzed by using liquid chromatography-tandem mass spectrometry. Peripheral blood mononuclear cells were evaluated for the profile of immune cells by multicolor flow-cytometry. Overall response rate was 68.6 % and 3-year progression-free survival was 57.2%. In a multivariate logistic analysis, AUC0-24 was a significant predictor for grade ≧ 2 hematologic AEs and trough level (C0) for grade ≧ 2 non-hematologic AEs. After Len therapy, effector memory subset and intracellular cytokine productions CD4 and CD8 T cells increased significantly.
|
Report
(4 results)
Research Products
(4 results)
-
-
-
[Presentation] 移植非適応未治療多発性骨髄腫患者に対するLd療法およびレナリドミドの至適血漿中濃度の検討2017
Author(s)
小林 敬宏, 三浦 昌朋, 新岡 丈典, 鐙屋 舞子, 大八木 秀明, 篠原 良徳, 茂木 睦仁, 黒木 淳, 西成 民夫, 川 端 良成, 北林 淳, 道下 吉広, 池田 翔, 志田 青慈, 吉岡 智子, 高橋 直人
Organizer
日本骨髄腫学会
Place of Presentation
東京
Year and Date
2017-05-27
Related Report
-